Quantum BioPharma signs Study Start‑Up Agreement with Thermo Fisher to launch Phase 2 Lucid‑MS trial
Quantum BioPharma Ltd. entered a Study Start‑Up Agreement with Thermo Fisher Scientific’s PPD Clinical Research business to implement a Phase 2 trial of its investigational drug Lucid‑MS for progressive multiple sclerosis. The trial, cleared by the FDA, will be a randomized, double‑blind, placebo‑controlled study evaluating efficacy, safety and tolerability. The partnership was announced by CEO Zeeshan Saeed and marks the operational start of the study.
Why it matters
The agreement moves Lucid‑MS into the next development stage, creating a near‑term catalyst for Quantum BioPharma as investors watch enrollment and trial results. Thermo Fisher’s involvement provides experienced CRO support, which may reduce execution risk, according to the company’s press release.
Key facts
- 1Quantum BioPharma signed a Study Start‑Up Agreement with Thermo Fisher Scientific’s clinical research business to implement the Phase 2 Lucid‑MS trial. globenewswire.com
- 2The FDA cleared the investigational new drug application for the Phase 2 trial on August 10, 2026. mugglehead.com
- 3The Phase 2 study will be randomized, double‑blind and placebo‑controlled. globenewswire.com
- 4CEO Zeeshan Saeed said the agreement represents an important next step for the program. globenewswire.com
- 5Quantum BioPharma owns 19.84% of Unbuzzd Wellness and receives royalties from its sales. citybuzz.co
Summary written by AlphAI from 20 of 20 sources. Not investment advice. Figures are as stated by the linked sources.